Google’s AI System Can Detect Breast Cancer Better Than Doctors

Managed Healthcare Executive | January 06, 2020

An artificial intelligence (AI) system developed by Google reportedly surpasses expert radiologists in accurately interpreting mammograms from screening programs, according to a new study published in Nature. In the study, which tested the accuracy of the system and developed through a collaboration between Google and cancer researchers, the authors report that the AI system outperformed both the historical decisions made by the radiologists who initially assessed the mammograms, and the decisions of six expert radiologists who interpreted 500 randomly selected cases in a controlled study. “The use of AI in healthcare is something clinicians have long anticipated—and even welcome,” says Jay Anders, MD, chief medical officer for Medicomp Systems, a provider of physician-driven point-of-care solutions that fix EHRs using clinical AI.

Spotlight

Pharmaceutical and Healthcare companies have shown an increased preference towards LinkedIn, which has come out on top followed by Facebook and Twitter for digital engagement as per data revealed by the India Digital Health Report 2017. The India Digital Health Report 2017 of more than 160 companies from the following verticals, pharmaceuticals, medical devices & equipment, diagnostics and hospitals on 12 key digital and social parameters – websites, apps, Facebook, Twitter, LinkedIn, YouTube, Google+, Blogger, Pinterest, Flickr, Instagram and Tumblr.

Spotlight

Pharmaceutical and Healthcare companies have shown an increased preference towards LinkedIn, which has come out on top followed by Facebook and Twitter for digital engagement as per data revealed by the India Digital Health Report 2017. The India Digital Health Report 2017 of more than 160 companies from the following verticals, pharmaceuticals, medical devices & equipment, diagnostics and hospitals on 12 key digital and social parameters – websites, apps, Facebook, Twitter, LinkedIn, YouTube, Google+, Blogger, Pinterest, Flickr, Instagram and Tumblr.

Related News

BUSINESS INSIGHTS

Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit

Resilience | February 16, 2022

National Resilience, Inc. a technology-focused manufacturing company dedicated to broadening access to complex medicines, announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit. As part of the agreement, Resilience will focus on supporting the development and manufacture of multiple products in Takeda’s plasma-derived medicines portfolio out of its facility in Mississauga, Ontario. “I’m proud to establish this relationship with Takeda, a company that has been pioneering plasma-derived therapies for more than 75 years. By bringing new technologies and innovation to biomanufacturing, we aim to help companies like Takeda reach more patients in need.” Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience Resilience’s 136,000 sq ft (12,800 m2) biomanufacturing facility in Mississauga provides process and analytical development, scale up, drug substance and drug product / fill finish manufacturing for a variety of medicines. “We are delighted to form this strategic collaboration with Resilience, leveraging their expertise in both plasma therapy development and manufacturing to complement our current infrastructure and capabilities,” said Andreas Liebminger, Head of Pharmaceutical Sciences and Devices for the Plasma-Derived Therapies Business Unit at Takeda. “Our partnership will allow us to optimally use our combined assets to continue to bolster our portfolio, drive innovation and help more patients around the world realize the benefits of plasma medicines.” About Resilience Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives.

Read More

PHARMACY MARKET

Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regulatory approvals to execute phase 3 and has recruited leading uveitis experts as principal investigators. Tarsier plans to enroll the first patient in Q4 of 2021. Tarsier's technology, TRS, is a novel immunomodulator molecule that showed, in a dose-ranging, randomized, double-masked phase I\II trial in the target indication, a prompt and statistically significant improvement in signs and symptoms of uveitis. "We are excited to have the support of our existing and new investors, as we continue our clinical development of TRS01 in advanced stages," said Dr. Haim Langford, CEO of Tarsier. "Looking ahead, we are eager to bring our lead product to market and simultaneously progress our development of important pipeline projects for other back-of -the-eye blinding diseases, and plan to raise additional capital to realize these as well." About Tarsier Pharma Tarsier Pharma is a late clinical stage pharmaceutical company, phase-3 ready, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a breakthrough proprietary technology platform, based on a new bio-inspired chemical entity, with novel mechanism of action and demonstrated safety and efficacy in a rare debilitating and blinding indication. Lead product candidate for uveitic glaucoma Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier's TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided, due to their negative side effects in expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma.

Read More

PHARMACY MARKET

Novartis' Sandoz spotlights importance of generic drugs in new social campaign

Novartis | December 17, 2020

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with messages running on LinkedIn and Twitter. Sandoz plans to run the mission through the finish of the principal quarter, perhaps more, contingent upon results. It's as of now chipping away at a second stage that will move center to biosimilar adaptations of marked biologic medications. "Generics are assuming a truly significant job, and I believe it's ideal planning currently to discuss the significant job generics play in a well-working medical care framework," said Carol Lynch, Sandoz's U.S. president and head of North America. Other than featuring the pervasiveness of generics, the online media posts promote their reasonableness and their status as firmly directed items—as protected and powerful as their image name partners. The moderateness and security messages are significant, alongside the general token of the opposition generics give in the commercial center. The duplicates of costlier marked medications help to make "a sound serious market that is directed to patients having expanded admittance to the prescriptions they need," Lynch said. Nonexclusive medications saved the U.S. medical services framework $313 billion a year ago, as per the 2020 yearly report of conventional and biosimilar access and reserve funds in the U.S. from the Association for Accessible Medicines, a generics industry exchange gathering.

Read More